Showing 1136 results
-
Press release /New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
-
Press release /US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated…
-
Press release /Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program…
-
Press release /Shareholders approve 22nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of…
-
Press release /Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients Combined…
-
Press release /Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY…
-
Press release /Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)…
-
Press release /Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
-
Press release /Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing…